Bespoke Extracts (BSPK) Consolidated Net Income (2011 - 2025)
Bespoke Extracts' (BSPK) quarterly Consolidated Net Income came in at -$78088.0 in Q3 2025, up 71.67% year-on-year from -$45487.9 in Q3 2024, and up 61.93% quarter-over-quarter from -$205106.0 in Q2 2025.
Bespoke Extracts (BSPK) Consolidated Net Income (2011 - 2025) Analysis & Trends
Bespoke Extracts has disclosed Consolidated Net Income across 15 years of filings, most recently posting -$78088.0 for Q3 2025.
- Consolidated Net Income for Q3 2025 came in at -$78088.0, up 71.67% year-over-year; the trailing twelve-month figure through Sep 2025 was -$730564.0 (up 34.75% YoY), and the FY2024 annual result was -$1.0 million, up 30.03% from the prior year.
- Consolidated Net Income came in at -$78088.0 for Q3 2025 at Bespoke Extracts, up from -$205106.0 in the prior quarter.
- In the past five years, Consolidated Net Income ranged from a high of $3.6 million in Q3 2021 to a low of -$1.1 million in Q3 2022.
- The 5-year median for Consolidated Net Income is -$299571.0 (2021), against an average of -$208527.6.
- Across the five-year window, Consolidated Net Income surged 212.31% in 2021 and rose 8.59% in 2024, its largest moves.
- Bespoke Extracts' Consolidated Net Income stood at $226984.0 in 2021, then slumped by 539.51% to -$997626.0 in 2022, then surged by 73.03% to -$269087.0 in 2023, then surged by 30.56% to -$186849.0 in 2024, then surged by 58.21% to -$78088.0 in 2025.
- The last three Consolidated Net Income figures came in at -$78088.0 (Q3 2025), -$205106.0 (Q2 2025), and -$260521.0 (Q1 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Consol Net Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 370.00 Mn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | 601.00 Mn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | 274.90 Mn |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | -114,733.81 |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | 197.90 Mn |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | 57.00 Mn |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | -66.53 Mn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | -92.12 Mn |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | 118.42 Mn |
| 10 | Bespoke Extracts | - | - | 234,175.00 | -78,088.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -78,088.00 |
| Jun 30, 2025 | -205,106.00 |
| Mar 31, 2025 | -260,521.00 |
| Dec 31, 2024 | -186,849.00 |
| Sep 30, 2024 | -275,613.00 |
| Jun 30, 2024 | -260,895.00 |
| Mar 31, 2024 | -314,118.00 |
| Dec 31, 2023 | -269,087.00 |
| Sep 30, 2023 | -301,529.00 |
| Jun 30, 2023 | -464,915.00 |
| Mar 31, 2023 | -440,620.00 |
| Dec 31, 2022 | -997,626.00 |
| Sep 30, 2022 | -1.13 Mn |
| Jun 30, 2022 | -1.01 Mn |
| Mar 31, 2022 | -972,494.00 |
| Nov 30, 2021 | 226,984.00 |
| Aug 31, 2021 | 3.59 Mn |
| May 31, 2021 | -299,571.00 |
| Feb 28, 2021 | -304,171.00 |
| Nov 30, 2020 | -202,106.00 |